Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation

13.05.25 16:35 Uhr

Werte in diesem Artikel

SAN DIEGO, May 13, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX).

Shareholders Foundation
mail@shareholdersfoundation.com
(8585)779-1554 (PRNewsfoto/Shareholders Foundation, Inc.)

Investors who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) prior to August 2023 and continue to hold any of those NASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On January 13, 2025, a NASDAQ: PCRX investor filed a lawsuit against Pacira BioSciences, Inc. over alleged violations of securities laws. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that Pacira had sufficient patent protections on Exparel, and as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue, that Pacira knew that the '495 patent was not as protective as Pacira publicly touted because on June 6, 2023, the United States District Court for the District of New Jersey issued a ruling in eVenus Pharmaceutical Laboratories, Inc.'s favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel, and that therefore, when the '495 patent was invalidated in another case Pacira filed against eVenus, investors and analysts alike were shocked by the concerning news that Exparel, which accounts for approximately 80% of Pacira's revenue, did not have sufficient patent protection to prevent another company from producing a generic during the life of the patent.

Those who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation, Inc.

CONTACT:
Shareholders Foundation, Inc. 
Michael Daniels 
+1 (858) 779-1554 
mail@shareholdersfoundation.com 
3111 Camino Del Rio North 
Suite 423 
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lawsuit-for-investors-in-shares-of-pacira-biosciences-inc-nasdaq-pcrx-announced-by-the-shareholders-foundation-302453795.html

SOURCE Shareholders Foundation, Inc.

In eigener Sache

Übrigens: Pacira Pharmaceuticals und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Pacira Pharmaceuticals

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Pacira Pharmaceuticals

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Pacira Pharmaceuticals Inc.

Wer­bung

Analysen zu Pacira Pharmaceuticals Inc.

DatumRatingAnalyst
11.06.2019Pacira Pharmaceuticals OverweightBarclays Capital
09.04.2018Pacira Pharmaceuticals BuyH.C. Wainwright & Co.
21.03.2018Pacira Pharmaceuticals NeutralMizuho
16.02.2018Pacira Pharmaceuticals HoldNeedham & Company, LLC
19.01.2018Pacira Pharmaceuticals BuySeaport Global Securities
DatumRatingAnalyst
11.06.2019Pacira Pharmaceuticals OverweightBarclays Capital
09.04.2018Pacira Pharmaceuticals BuyH.C. Wainwright & Co.
19.01.2018Pacira Pharmaceuticals BuySeaport Global Securities
04.01.2018Pacira Pharmaceuticals BuyCanaccord Adams
09.11.2017Pacira Pharmaceuticals BuyH.C. Wainwright & Co.
DatumRatingAnalyst
21.03.2018Pacira Pharmaceuticals NeutralMizuho
16.02.2018Pacira Pharmaceuticals HoldNeedham & Company, LLC
29.11.2017Pacira Pharmaceuticals NeutralMizuho
30.12.2016Pacira Pharmaceuticals NeutralJanney
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pacira Pharmaceuticals Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen